16. A compound according to any one of claims 13-15, wherein D is $-CO_2H$.

17. A compound according to any one of claims 13-16, wherein E is null.

18. A compound according to any one of claims 13-17, wherein x is 4 to 6.

19. A compound according to any one of claims 13-18, wherein y is 0 to 1 and w is 2.

20. A compound according to any one of claims 13-19, wherein z is 0 to 2.

21. A compound according to any one of claims 13-20, wherein x is 5.

22. A compound according to any one of claims 13-21, wherein y is 0.

23. A compound according to any one of claims 13-22, wherein z is 1.

24. A compound according to any one of claims 13-23, wherein both R^d are hydrogen.

25. A compound according to claim 1, wherein x = 5, y = 0, z = 1, both R^d are hydrogen, A is 

, D is $-CO_2H$, and E is null.

26. A compound according to claim 25, wherein D is at the *para* position on the phenyl group.

27. A compound as listed in Table 1.

28. A compound as listed in Table 2.

29. A composition comprising a compound according to any one of claims 1 to 28 and at least one pharmaceutically acceptable excipient.

30. The use of a compound according to any one of claims 1 to 28, or a composition according to claim 29 in the manufacture of a medicament for treating or preventing hepatitis C virus infection or reactivation in a host.

31. The use of a compound according to any one of claims 1 to 28, or a composition according to claim 29 in the manufacture of a medicament for reducing a hepatitis C virus polymerase activity in a host.

32. A use of a compound according to any one of claims 1 to 28, or a composition according to claim 29 in the manufacture of a medicament ofr reducing hepatitis C virus replication in a host.

33. The use according to any of claims 30-32, wherein the host is to be further administered with at least one active agent selected from the group consisting of interferons, ribavirin, nucleoside HCV NS5B polymerase inhibitors, non-nucleoside HCV NS5B polymerase inhibitors, HCV NS3-4A protease inhibitors, HCV NS5A inhibitors, HCV entry inhibitors, HCV NS3 inhibitors, HCV NS3 helicase inhibitors, HCV NS4B inhibitors, and human cyclophilin inhibitors.

34. A combination, comprising a compound of any of claims 1-28, together with at least one active agent selected from interferons, ribavirin, nucleoside HCV NS5B polymerase inhibitors, non-nucleoside HCV NS5B polymerase inhibitors, HCV NS3-4A protease inhibitors, HCV NS5A inhibitors, HCV entry inhibitors, HCV NS3 inhibitors, HCV NS3 helicase inhibitors, HCV NS4B inhibitors, and human cyclophilin inhibitors.

35. A combination, comprising a composition of claim 29, together with a composition comprising at least one active agent selected from interferons, ribavirin, nucleoside HCV NS5B polymerase inhibitors, non-nucleoside HCV NS5B polymerase inhibitors, HCV NS3-4A protease inhibitors, HCV NS5A inhibitors, HCV entry inhibitors, HCV NS3 inhibitors, HCV NS3 helicase inhibitors, HCV NS4B inhibitors, and human cyclophilin inhibitors and a pharmaceutically acceptable excipient.